Skip to content

#398 What's 340B? An Economist's View of the Recent Wave of 340B Litigation

October 5, 2026 · 27 min

Show notes

The Federal 340B Drug Pricing Program has grown from a modest drug discount program into a massive federal program involving pharmaceutical manufacturers, hospitals, pharmacies, insurers, and third-party administrators. But when can similar conduct by participants in this program suggest coordination or raise other competition concerns? Archan Ruparel, economist at Charles River Associates, joins Brian Auricchio and Jaclyn Phillips to discuss economic considerations when evaluating potential antitrust concerns relating to 340B. Listen to this episode to learn more about factors that can help analyze this conduct.


With special guest:
Archan Ruparel, Charles River Associates

Hosted by:
Brian Auricchio, Haug Partners and Jaclyn Phillips, Proskauer Rose

All episodes of Our Curious Amalgam

Settings

Display

Language

Decides which stations you see first on the home page.

History

Recently played stations and episodes and your latest searches are only stored in this browser.

Notifications

A short notice when a podcast you follow has a new episode. Turn off single podcasts with the bell on their page.

Account

Save favorites – in the app and on the website.

Keyboard shortcuts

/
Open search
Space
Play or pause
← →
In the player: back 15 s, forward 30 s (episodes) · in a row: next tile
↑ ↓
In a row: target within the tile
Home / End
In a row: first or last tile
Esc
Close window or menu
?
This overview
Now playing

Go to station page

Play next

    Add episodes with “Play next” – they play after the current episode.